Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Next Science had a gross margin of 83.17% for the quarter that ended in Jun. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Next Science Gross Margin % Related Terms
Next Science Gross Margin % Historical Data
* Premium members only.
The historical data trend for Next Science's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NXS vs GCAN, PTPI, GRPS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Next Science Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Next Science's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Next Science's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Next Science (ASX:NXS) has a Gross Margin % of 83.17% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Next Science and its competitors. This is near median its historical median of 79.48. Over the past decade, Next Science's Gross Margin % has ranged from 73.20 to 86.43.
Is Next Science's Gross Margin % too high?
Next Science's current Gross Margin % of 83.17% is near median its 10-year median of 79.48. Over the past 10 years, this metric has ranged from a low of 73.20 to a high of 86.43. The Drug Manufacturers industry median Gross Margin % is 48.51. Next Science's value of 83.17% is 71.4% above this industry median. Overall, Next Science has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Next Science's Gross Margin % compare to GCAN and PTPI?
Next Science's Gross Margin % of 83.17% can be compared against companies in the Drug Manufacturers industry. The industry median Gross Margin % is 48.51. Next Science's value of 83.17% is 71.4% above this benchmark. Historically, Next Science's own Gross Margin % has ranged from 73.20 to 86.43 over the past decade. While the company's 10-year median is 79.48 vs. the industry median of 48.51, Next Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.51, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Next Science's current Gross Margin % of 83.17% is 71.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Next Science and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Next Science's current Gross Margin % is 83.17%, which is near median its own 10-year median of 79.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (ASX:NXS) has a current Gross Margin % of 83.17%. The stock's GF Value™ is A$37.70, compared to a current price of A$0.15 — trading 99.6% below its estimated fair value. The current Gross Margin % is 83.17%, which is near median its 10-year median of 79.48 and 71.4% above the Drug Manufacturers industry median of 48.51. Next Science's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Next Science (ASX:NXS), the current Gross Margin % is 83.17% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Next Science (ASX:NXS) Overvalued in 2026?
Based on GuruFocus' analysis, Next Science stock appears to be undervalued.
The current stock price of A$0.15 is trading 99.6% below its estimated GF Value™ of A$37.70.
Key valuation signals for ASX:NXS:
Gross Margin %: 83.17% (near median its 10-year median of 79.48)
GF Value™: A$37.70 vs. price of A$0.15 (99.6% below fair value)
Industry Position: 71.4% above the Drug Manufacturers median
No single metric tells the full story. See the ASX:NXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
25GF Score
Get the complete analysis for ASX:NXS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NXS has been successfully added to your 
